These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34975201)

  • 1. WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
    Omrčen T
    Acta Clin Croat; 2019 Nov; 58(Suppl 2):69-72. PubMed ID: 34975201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
    Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
    Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone naïve metastatic prostate cancer: How to treat it?
    Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
    Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.
    Afferi L; Longoni M; Moschini M; Gandaglia G; Morgans AK; Cathomas R; Mattei A; Breda A; Scarpa RM; Papalia R; de Nunzio C; Esperto F
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):173-182. PubMed ID: 37055663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Hoyle AP; Ali A; James ND; Cook A; Parker CC; de Bono JS; Attard G; Chowdhury S; Cross WR; Dearnaley DP; Brawley CD; Gilson C; Ingleby F; Gillessen S; Aebersold DM; Jones RJ; Matheson D; Millman R; Mason MD; Ritchie AWS; Russell M; Douis H; Parmar MKB; Sydes MR; Clarke NW;
    Eur Urol; 2019 Dec; 76(6):719-728. PubMed ID: 31447077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
    Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
    Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
    Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
    Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Mutlu H; Bozcuk H
    J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
    Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
    Kinsey EN; Zhang T; Armstrong AJ
    Cancer J; 2020; 26(1):64-75. PubMed ID: 31977388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.